Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2019 Jun 11;119(4):368–380. doi: 10.1254/jphs.12124FP

Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With α-Alkyl Moieties

Narakorn Khunweeraphong 1,2,†, Shushi Nagamori 1,†, Pattama Wiriyasermkul 1, Yumiko Nishinaka 1,#, Printip Wongthai 1, Ryuichi Ohgaki 1, Hidekazu Tanaka 1, Hideyuki Tominaga 3, Hiroyuki Sakurai 2, Yoshikatsu Kanai 1,*
PMCID: PMC7128428  PMID: 22850614

Abstract

System L is a major transport system for cellular uptake of neutral amino acids. Among system L transporters, L-type amino acid transporter 1 (LAT1) is responsible for the nutrient uptake in cancer cells, whereas L-type amino acid transporter 2 (LAT2) is a transporter for non-cancer cells. In this study, we have established HEK293 cell lines stably expressing high levels of human LAT1 and LAT2 forming heterodimers with native human 4F2hc of the cells. We have found that l-[14C]alanine is an appropriate substrate to examine the function of LAT2, whereas l-[14C]leucine is used for LAT1. By using l-[14C]alanine on LAT2, we have for the first time directly evaluated the function of human LAT2 expressed in mammalian cells and obtained its reliable kinetics. Using α-alkyl amino acids including α-methyl-alanine and α-ethyl-l-alanine, we have demonstrated that α-alkyl groups interfere with the interaction with LAT2. These cell lines with higher practical advantages would be useful for screening and analyzing compounds to develop LAT1-specific drugs that can be used for cancer diagnosis and therapeutics. The strategy that we took to establish the cell lines would also be applicable to the other heterodimeric transporters with important therapeutic implications.

Keywords: transporter, amino acid, system L, blood–brain barrier, cancer

References

  • 1.Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70:43–77. doi: 10.1152/physrev.1990.70.1.43. [DOI] [PubMed] [Google Scholar]
  • 2.Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98) J Biol Chem. 1998;273:23629–23632. doi: 10.1074/jbc.273.37.23629. [DOI] [PubMed] [Google Scholar]
  • 3.Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999;274:19745–19751. doi: 10.1074/jbc.274.28.19745. [DOI] [PubMed] [Google Scholar]
  • 4.Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 2004;447:532–542. doi: 10.1007/s00424-003-1086-z. [DOI] [PubMed] [Google Scholar]
  • 5.Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291–302. doi: 10.1016/s0005-2736(01)00384-4. [DOI] [PubMed] [Google Scholar]
  • 6.Matsuo H, Tsukada S, Nakata T, Chairoungdua A, Kim DK, Cha SH. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport. 2000;11:3507–3511. doi: 10.1097/00001756-200011090-00021. [DOI] [PubMed] [Google Scholar]
  • 7.Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer. 2009;66:120–126. doi: 10.1016/j.lungcan.2008.12.015. [DOI] [PubMed] [Google Scholar]
  • 8.Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742–748. doi: 10.1038/sj.bjc.6604235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N. Comparison of L-type amino acid transporter 1 expression and l-[3-18F]-alpha-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol. 2010;37:911–916. doi: 10.1016/j.nucmedbio.2010.06.004. [DOI] [PubMed] [Google Scholar]
  • 10.Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009;50:1770–1776. doi: 10.2967/jnumed.109.066837. [DOI] [PubMed] [Google Scholar]
  • 11.Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 2009;59:7–18. doi: 10.1111/j.1440-1827.2008.02319.x. [DOI] [PubMed] [Google Scholar]
  • 12.Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119:484–492. doi: 10.1002/ijc.21866. [DOI] [PubMed] [Google Scholar]
  • 13.Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 2008;62:493–503. doi: 10.1227/01.neu.0000316018.51292.19. discussion 503–504. [DOI] [PubMed] [Google Scholar]
  • 14.Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254–266. doi: 10.1016/j.semcancer.2005.04.005. [DOI] [PubMed] [Google Scholar]
  • 15.Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab. 2001;2:339–354. doi: 10.2174/1389200013338324. [DOI] [PubMed] [Google Scholar]
  • 16.Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Lett. 2009;276:95–101. doi: 10.1016/j.canlet.2008.10.035. [DOI] [PubMed] [Google Scholar]
  • 17.Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136:521–534. doi: 10.1016/j.cell.2008.11.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010;101:173–179. doi: 10.1111/j.1349-7006.2009.01386.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kim DK, Kanai Y, Choi HW, Tangtrongsup S, Chairoungdua A, Babu E. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta. 2002;1565:112–121. doi: 10.1016/s0005-2736(02)00516-3. [DOI] [PubMed] [Google Scholar]
  • 20.Kanai Y, Endou H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J Toxicol Sci. 2003;28:1–17. doi: 10.2131/jts.28.1. [DOI] [PubMed] [Google Scholar]
  • 21.Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61:729–737. doi: 10.1124/mol.61.4.729. [DOI] [PubMed] [Google Scholar]
  • 22.Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369–6378. doi: 10.1158/1078-0432.CCR-07-1294. [DOI] [PubMed] [Google Scholar]
  • 23.Detta A, Cruickshank GS. l-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 2009;69:2126–2132. doi: 10.1158/0008-5472.CAN-08-2345. [DOI] [PubMed] [Google Scholar]
  • 24.Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, et al. Transport of 3-fluoro-l-α-methyl tyrosine by tumor-upregulated amino acid transporter LAT1: a cause of the tumor uptake in PET. J Nucl Med. In press [DOI] [PubMed]
  • 25.Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem. 1999;274:34948–34954. doi: 10.1074/jbc.274.49.34948. [DOI] [PubMed] [Google Scholar]
  • 26.Broer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev. 2008;88:249–286. doi: 10.1152/physrev.00018.2006. [DOI] [PubMed] [Google Scholar]
  • 27.Roos S, Kanai Y, Prasad PD, Powell TL, Jansson T. Regulation of placental amino acid transporter activity by mammalian target of rapamycin. Am J Physiol Cell Physiol. 2009;296:C142–C150. doi: 10.1152/ajpcell.00330.2008. [DOI] [PubMed] [Google Scholar]
  • 28.Loubiere LS, Vasilopoulou E, Bulmer JN, Taylor PM, Stieger B, Verrey F. Expression of thyroid hormone transporters in the human placenta and changes associated with intrauterine growth restriction. Placenta. 2010;31:295–304. doi: 10.1016/j.placenta.2010.01.013. [DOI] [PubMed] [Google Scholar]
  • 29.Kido Y, Tamai I, Uchino H, Suzuki F, Sai Y, Tsuji A. Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier. J Pharm Pharmacol. 2001;53:497–503. doi: 10.1211/0022357011775794. [DOI] [PubMed] [Google Scholar]
  • 30.Morimoto E, Kanai Y, Kim DK, Chairoungdua A, Choi HW, Wempe MF. Establishment and characterization of mammalian cell lines stably expressing human l-type amino acid transporters. J Pharmacol Sci. 2008;108:505–516. doi: 10.1254/jphs.08232fp. [DOI] [PubMed] [Google Scholar]
  • 31.Kim DK, Kanai Y, Choi HW, Tangtrongsup S, Chairoungdua A, Babu E. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta. 2002;1565:112–121. doi: 10.1016/s0005-2736(02)00516-3. [DOI] [PubMed] [Google Scholar]
  • 32.Kurayama R, Ito N, Nishibori Y, Fukuhara D, Akimoto Y, Higashihara E. Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis. Lab Invest. 2011;91:992–1006. doi: 10.1038/labinvest.2011.43. [DOI] [PubMed] [Google Scholar]
  • 33.Takeda M, Sekine T, Endou H. Regulation by protein kinase C of organic anion transport driven by rat organic anion transporter 3 (rOAT3) Life Sci. 2000;67:1087–1093. doi: 10.1016/s0024-3205(00)00694-9. [DOI] [PubMed] [Google Scholar]
  • 34.Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59–74. doi: 10.1099/0022-1317-36-1-59. [DOI] [PubMed] [Google Scholar]
  • 35.Babu E, Takeda M, Nishida R, Noshiro-Kofuji R, Yoshida M, Ueda S. Interactions of human organic anion transporters with aristolochic acids. J Pharmacol Sci. 2010;113:192–196. doi: 10.1254/jphs.09339sc. [DOI] [PubMed] [Google Scholar]
  • 36.Choi KS, Aizaki H, Lai MM. Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release. J Virol. 2005;79:9862–9871. doi: 10.1128/JVI.79.15.9862-9871.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Miyamoto N, Higuchi Y, Tsurudome M, Ito M, Nishio M, Kawano M. Induction of c-Src in human blood monocytes by anti-CD98/FRP-1 mAb in an Sp1-dependent fashion. Cell Immunol. 2000;204:105–113. doi: 10.1006/cimm.2000.1696. [DOI] [PubMed] [Google Scholar]
  • 38.Sakamoto S, Chairoungdua A, Nagamori S, Wiriyasermkul P, Promchan K, Tanaka H. A novel role of the C-terminus of b0,+AT in the ER-Golgi trafficking of the rBAT-b0,+AT heterodimeric amino acid transporter. Biochem J. 2009;417:441–448. doi: 10.1042/BJ20081798. [DOI] [PubMed] [Google Scholar]
  • 39.Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291–302. doi: 10.1016/s0005-2736(01)00384-4. [DOI] [PubMed] [Google Scholar]
  • 40.Broer S, Broer A, Hansen JT, Bubb WA, Balcar VJ, Nasrallah FA. Alanine metabolism, transport, and cycling in the brain. J Neurochem. 2007;102:1758–1770. doi: 10.1111/j.1471-4159.2007.04654.x. [DOI] [PubMed] [Google Scholar]
  • 41.Nawashiro H, Otani N, Uozumi Y, Ooigawa H, Toyooka T, Suzuki T. High expression of L-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathol. 2005;22:89–91. doi: 10.1007/s10014-005-0188-z. [DOI] [PubMed] [Google Scholar]
  • 42.Shikano N, Kanai Y, Kawai K, Inatomi J, Kim DK, Ishikawa N. Isoform selectivity of 3-125I-iodo-alpha-methyl-l-tyrosine membrane transport in human L-type amino acid transporters. J Nucl Med. 2003;44:244–246. [PubMed] [Google Scholar]
  • 43.Shikano N, Kanai Y, Kawai K, Ishikawa N, Endou H. Characterization of 3-[125I]iodo-alpha-methyl-l-tyrosine transport via human L-type amino acid transporter 1. Nucl Med Biol. 2003;30:31–37. doi: 10.1016/s0969-8051(02)00350-5. [DOI] [PubMed] [Google Scholar]
  • 44.Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H. Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer. 2009;124:1152–1160. doi: 10.1002/ijc.24034. [DOI] [PubMed] [Google Scholar]
  • 45.Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake--the role of PET/CT. Eur Radiol. 2006;16:1054–1065. doi: 10.1007/s00330-005-0088-y. [DOI] [PubMed] [Google Scholar]
  • 46.Fukasawa Y, Segawa H, Kim JY, Chairoungdua A, Kim DK, Matsuo H. Identification and characterization of a Na+-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral d- and l-amino acids. J Biol Chem. 2000;275:9690–9698. doi: 10.1074/jbc.275.13.9690. [DOI] [PubMed] [Google Scholar]
  • 47.Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19:387–400. doi: 10.1016/j.ccr.2011.01.038. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Pharmacological Sciences are provided here courtesy of Elsevier

RESOURCES